Rimacalib, a inhibitor of CaMKII, inhibits VEGF expression in human acute monocytic leukemia cell and SF macrophage obtained from patient with rheumatoid arthritis. This effect may contribute to the anti-arthritic effects of Rimacalib. The IC50s of Rimacalib are ~1uM for CaMKIIα to ~30uM for CaMKIIγ.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.